SCHEMBL3345136

SCHEMBL3345136

NN(C(=O)c1ccc(Cl)cc1)c1nc(-c2cc3ccccc3o2)cs1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
CSNK2A1 P68400 1/20 0.48
CYP19A1 P11511 1/20 0.46
CA12 O43570 1/20 0.46
CA9 Q16790 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
LMNA P02545 2/20 0.45
HPGD P15428 2/20 0.45
HTT P42858 2/20 0.45
MAPK1 P28482 2/20 0.45
KDM4E B2RXH2 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
GRM1 Q13255 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
STAT1 P42224 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4797120 0.80 GRM1 (0.59) MAPTNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL4798879 0.78 NPC1 (0.59) MAPTNPC1RAB9ACYP19A1SMN1; SMN2
SCHEMBL4798725 0.77 CSNK2A1 (0.54) MAPTNPC1RAB9ACSNK2A1CA12
SCHEMBL4780298 0.76 MIF (0.53) MAPTNPC1RAB9ACSNK2A1CA12
SCHEMBL3337628 0.74 CA12 (0.78) MAPTCSNK2A1CA12CA9SMN1; SMN2
SCHEMBL4784287 0.72 CA12 (0.51) MAPTNPC1RAB9ACSNK2A1CA12
SCHEMBL4798176 0.71 GRM1 (0.55) MAPTNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL4797456 0.70 GRM1 (0.48) MAPTNPC1RAB9ACSNK2A1SMN1; SMN2
SCHEMBL4806014 0.69 NPC1 (0.52) MAPTNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL3341175 0.69 GRM1 (0.59) MAPTNPC1RAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
WO-2008052804-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2008-05-08 WO claimed
WO-2008052804-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA MAPT 2/4885NPC1 36/4885RAB9A 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.